Altimmune ALT Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's accretion (amortization) of discounts and premiums, investments?
- Altimmune (ALT) reported accretion (amortization) of discounts and premiums, investments of $870K in Q1 2026.
- How has Altimmune's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Altimmune's accretion (amortization) of discounts and premiums, investments increased by 26.8% year-over-year, from $686K to $870K.
- What is the long-term trend for Altimmune's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2022 to 2025), Altimmune's accretion (amortization) of discounts and premiums, investments has grown at a 47.1% compound annual growth rate (CAGR), from $698K to $2.22M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to interest income or expense resulting from the amortization of premiums or the accretion of discounts on held-to-maturity or available-for-sale investment securities. It reflects the gradual recognition of the difference between the purchase price and the face value of debt instruments over their remaining term. This adjustment is essential for reconciling net income to cash flow from operations by removing non-cash yield impacts.